GlobalData on MSN

Eli Lilly’s Ebglyss shows sustained skin clearance in atopic dermatitis trial

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...
The Pharma Letter

ICER revises cost-effectiveness analysis for Novo and Lilly obesity drugs

The Institute for Clinical and Economic Review (ICER) has updated its assessment of the value of Novo Nordisk’s (NOV: N) ...
Zacks.com on MSN

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?

LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...

Investor Outlook: Eli Lilly delivers another strong quarter as demand for GLP-1 drugs accelerates

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Eli Lilly partners with Nvidia to build pharma’s most powerful AI supercomputer

Eli Lilly & Co. has joined forces with artificial intelligence chipmaker Nvidia Corp. to develop what the companies describe as the most powerful supercomputer operated by a pharmaceutical firm. The ...